Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Rotavirus Infections - Overview Rotavirus Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Rotavirus Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Rotavirus Infections - Companies Involved in Therapeutics Development Beijing Minhai Biotechnology Co Ltd Bharat Biotech International Ltd Biological E Ltd Curevac AG GlaxoSmithKline Plc Medicago Inc Serum Institute of India Ltd UMN Pharma Inc Wuhan Institute of Biological Products Co Ltd Rotavirus Infections - Drug Profiles (rotavirus (virus like particle) + typhiod) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Rotavac-5C - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus (tetravalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Rotavirus (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile Product Description Mechanism Of Action R&D Progress Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress rotavirus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress RV-3BB - Drug Profile Product Description Mechanism Of Action R&D Progress RV-625 - Drug Profile Product Description Mechanism Of Action R&D Progress UMN-2001 - Drug Profile Product Description Mechanism Of Action R&D Progress Rotavirus Infections - Dormant Projects Rotavirus Infections - Product Development Milestones Featured News & Press Releases Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification Sep 26, 2017: Serum Institute's vaccine demonstrates significant efficacy against severe rotavirus Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus Apr 26, 2012: GSK’s Rotarix to Be Introduced in Ghana Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Rotavirus Infections, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Universities/Institutes, H1 2018 Number of Products by Stage and Target, H1 2018 Number of Products by Stage and Mechanism of Action, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018 Rotavirus Infections - Pipeline by Bharat Biotech International Ltd, H1 2018 Rotavirus Infections - Pipeline by Biological E Ltd, H1 2018 Rotavirus Infections - Pipeline by Curevac AG, H1 2018 Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H1 2018 Rotavirus Infections - Pipeline by Medicago Inc, H1 2018 Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H1 2018 Rotavirus Infections - Pipeline by UMN Pharma Inc, H1 2018 Rotavirus Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2018 Rotavirus Infections - Dormant Projects, H1 2018 List of Figures Number of Products under Development for Rotavirus Infections, H1 2018 Number of Products under Development by Companies, H1 2018 Number of Products under Development by Universities/Institutes, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Beijing Minhai Biotechnology Co Ltd Bharat Biotech International Ltd Biological E Ltd Curevac AG GlaxoSmithKline Plc Medicago Inc Serum Institute of India Ltd UMN Pharma Inc Wuhan Institute of Biological Products Co Ltd